These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39054323)

  • 1. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
    Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
    Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
    Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
    Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology and evolution of poorly differentiated neuroendocrine tumors.
    Rickman DS; Beltran H; Demichelis F; Rubin MA
    Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
    Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
    Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
    Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
    EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
    Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
    Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways.
    Sasi NK; Bhutkar A; Lanning NJ; MacKeigan JP; Weinreich M
    Neoplasia; 2017 May; 19(5):439-450. PubMed ID: 28448802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
    Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
    Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
    Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
    Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
    Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
    J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.
    Maclean KH; Dorsey FC; Cleveland JL; Kastan MB
    J Clin Invest; 2008 Jan; 118(1):79-88. PubMed ID: 18097482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
    Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
    Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells.
    Cao JX; Lu Y; Qi JJ; An GS; Mao ZB; Jia HT; Li SY; Ni JH
    Cell Death Dis; 2014 Sep; 5(9):e1426. PubMed ID: 25255219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.